This open-label, randomized, and multicentre trial tested the hypothesis that, on a background of aspirin, continuing clopidogrel would be superior to stopping clopidogrel at 12 months following drug-eluting stent (DES) implantation.
Patients (N ¼ 1799) who had undergone placement of ≥1 DES for stable coronary artery disease or acute coronary syndrome were included in 58 French sites (January 2009-January 2013). Patients (N ¼ 1385) free of major cardiovascular/cerebrovascular events or major bleeding and on aspirin and clopidogrel 12 months after stenting were eligible for randomization (1:1) between continuing clopidogrel 75 mg daily (extended-dual antiplatelet therapy, DAPT, group) or discontinuing clopidogrel (aspirin group). The primary outcome was net adverse clinical events defined as the composite of death, myocardial infarction, stroke, or major bleeding. Follow-up was planned from a minimum of 6 to a maximum of 36 months after randomization. Owing to slow recruitment, the study was stopped after enrolment of 1385 of a planned 1966 patients. Median follow-up after stenting was 33.4 months. The primary outcome occurred in 40 patients (5.8%) in the extended-DAPT group and 52 in the aspirin group (7.5%; hazard ratio 0.75, 95% confidence interval 0.50 -1.28; P ¼ 0.17). Rates of death were 2.3% in the extended-DAPT group and 3.5% in the aspirin group (HR 0.65, 95% CI 0.34 -1.22; P ¼ 0.18). Rates of major bleeding were identical (2.0%, P ¼ 0.95). 
Conclusions
Extended DAPT did not achieve superiority in reducing net adverse clinical events compared to 12 months of DAPT after DES placement. The power of the OPTIDUAL trial was however low and reduced by premature termination of enrolment.
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Dual antiplatelet therapy † Drug-eluting stent † Randomized trial † Clopidogrel † Bleeding † Myocardial infarction Background Drug-eluting stents (DES) have substantially improved the outcomes of patients with coronary artery disease undergoing percutaneous coronary intervention (PCI). 1 After implantation of a DES, patients are treated with dual antiplatelet therapy (DAPT) in which a P2Y 12 -receptor inhibitor is combined with aspirin to reduce the risk of stent thrombosis and minimize adverse cardiac outcomes. 2 Although stent thrombosis related to DES has become relatively rare with newer generation DES, it remains a lifethreatening event. 3 Dual antiplatelet therapy is currently recommended for at least 6 -12 months after implantation of a DES. 4, 5 However, the optimum duration of this therapy remains a matter of debate. Evidence from initial studies 6 -9 has suggested that extending the duration of DAPT increases the risk of bleeding but does not reduce the risk of thrombotic events. Likewise, data from some randomized studies have shown that shortening the duration of DAPT (to 3 -6 months) is associated with similar rates of major cardiovascular events but lower rates of bleeding compared with more-prolonged DAPT (i.e. 12 -24 months) 10 ; the median follow-up of these studies was 16.8 months. More-recent trials failed to demonstrate a benefit of prolonged DAPT after DES implantation: the ISAR-SAFE 11 and ITALIC 12 studies found no difference in net clinical outcome between 6 months and 12 months of clopidogrel therapy. However, the large DAPT trial 13 has shown that compared with aspirin therapy alone, prolonging DAPT for 18 months, 1 year after placement of a DES, reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. There was also a signal of increased all-cause mortality, driven by greater non-cardiovascular mortality due to bleeding, trauma, or cancer. Reconciling these results is difficult and underlines the need for more data regarding the appropriate duration of DAPT after stent implantation. In particular, few studies have addressed the specific question of very long-term DAPT, but their results suggest that the long-term risk of very late stent thrombosis is somewhat linear and low, particularly with the use of newer generations of stents 13 -15 ; consequently, if there is a benefit of extended DAPT in preventing late stent thrombosis, there is no particular reason to expect the risk to abate after 12 or 18 months. We therefore sought to explore the value of very long-term DAPT in improving clinical outcomes in this setting. The OPTImal DUAL antiplatelet therapy (OPTIDUAL) trial was designed to test whether prolonging clopidogrel after PCI would result in superior net clinical outcomes compared with stopping clopidogrel 12 months after PCI in patients who received a DES.
Methods
Study design
OPTIDUAL was an investigator-initiated, multicentre, open-label, randomized trial, with the aim of comparing the benefits and risks of DAPT continued for either 12 or 48 months after coronary stenting. 16 The investigators (listed in Supplementary material online, Appendix S1) are solely responsible for the design and conduct of the trial, for the data analyses, and for writing the manuscript and for its final content. The study protocol was approved by an independent ethics committee before study initiation (CPP 34-2008). The study was conducted in accordance with the principles of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guidelines, and applicable local laws and regulations.
Study population
Eligible patients had symptoms of stable angina, silent ischaemia, or acute coronary syndrome (i.e. unstable angina, non -ST-segment elevation myocardial infarction, or ST-segment elevation myocardial infarction) with ≥1 lesion with stenosis .50% located in a native vessel ≥2.25 mm in diameter and who were implanted with ≥1 DES of any type. The major exclusion criteria included requirement for oral anticoagulation, DES implantation in an unprotected left main coronary artery, and malignancies or other coexisting conditions associated with a life expectancy of ,2 years (Supplementary material online, Appendix S2). Patients implanted with a bare-metal stent during the same procedure were permitted to enrol in the study. All patients provided written informed consent.
Intervention
At 12 + 3 months after DES implantation, patients who were receiving DAPT (clopidogrel + aspirin) and who had remained free of major cardiovascular and cerebrovascular events or major bleeding were randomly assigned (1:1) to receive clopidogrel 75 mg daily (extended-DAPT group) for a further 36 additional months (total treatment duration with DAPT: 48 + 3 months) or to discontinue clopidogrel (aspirin group). Post-procedure use of aspirin (75 -160 mg daily according to local standards) was prescribed indefinitely. Patients who had received prasugrel (n ¼ 18, 1.3% of the randomized patients) instead of clopidogrel at the time of PCI were eligible for randomization provided they had been switched to clopidogrel ≥6 months before randomization. Randomization was stratified by centre using an interactive voice response system.
Clinical follow-up
Patient baseline characteristics, clinical and procedural information were captured at the time of the randomization. All patients were scheduled to undergo clinical follow-up every 6 months, from a minimum of 6 months to a maximum of 36 months after randomization; consequently each patient attended between one and six follow-up visits, at least one of which was at an office. Attendance at the office was not possible for 60.9% of follow-up visits; these were replaced by telephone calls done by dedicated and trained study coordinators/clinical research assistants who were experienced in reporting all hospitalizations and/or major events. The final follow-up visit was a clinical visit with the investigator.
Outcomes and definitions
The primary outcome was net adverse clinical events defined as the composite of all-cause mortality, non-fatal myocardial infarction, stroke, or major bleeding. Myocardial infarction was defined as the presence of clinical or electrocardiographic changes consistent with myocardial ischaemia in the setting of increased cardiac biomarkers above the upper limit of normal in accordance with the universal definition. 17 Strokes were categorized as ischaemic or haemorrhagic depending on the results of cerebral imaging. All events occurring after randomization were adjudicated by an independent clinical event committee (Supplementary material online, Appendix S1), blinded to randomization assignment. Detailed definitions of outcomes are available in Supplementary material online, Appendix S3.
Statistical considerations
The trial was designed as a superiority trial: a sample size of 983 patients per arm was calculated to provide 80% power to demonstrate a significant reduction in the primary composite outcome at 3 years postrandomization from 7% with aspirin alone to 4% with prolonged DAPT, using survival analysis based on a Cox model and a 5% two-sided significance level. 16 In July 2014, owing to lack of resources and slower enrolment than anticipated, the executive committee recommended termination of follow-up at the end of September 2014.
All analyses were performed according to the intention-to-treat principle, with the inclusion of all randomized patients according to the original group allocation. The primary and secondary outcomes related to time to an event were analysed in a survival analysis based on a Cox model. In case of missing values regarding the occurrence of events, patients were censored at the time of their last date of follow-up. The survival status during follow-up is described using Kaplan -Meier curves. In addition, since it cannot be excluded that patients who were censored differed from those who were still being followed (informative censoring), thus possibly inducing a bias, we performed an additional 'inverse probability of censoring' weighted analysis that incorporates confounders to account for potential imbalances due to censoring patterns. 22, 23 Other secondary outcomes were analysed with the chi-square or Fisher's exact test. The two-sided significance level was fixed at 5%. As the present study was not blinded, it was important to assess the effect of compliance with the randomized treatment on our results. Thus, we also performed sensitivity analyses: (i) a perprotocol analysis (treatment as attributed by randomization taken until the last follow-up visit, no premature discontinuation of the study); (ii) an 'as treated' analysis with all randomized patients analysed as a function of the treatment really taken (i.e. a patient randomized in the aspirin group but who received clopidogrel during their follow-up was considered to be in the extended-DAPT group. All tests were performed with SAS version 9.3 (SAS Institute Inc., Cary, NC, USA).
Results
Patients and procedures
Between January 2009 and January 2013, 1799 patients who had undergone DES implantation and were receiving DAPT were enrolled in the study. The majority of the patients (n ¼ 1396) were included just after DES implantation, the remainder at 12 + 3 months after DES implantation. At 12 + 3 months after DES implantation, 401 of the 1396 patients included just after PCI were not randomized. At randomization (mean + SD 12 + 3 months later), 1398 patients who were on DAPT and were free of myocardial infarction, stroke, or major bleeding in the intervening period were randomly assigned to receive a further 36 months of DAPT with clopidogrel (75 mg/day) plus aspirin (extended-DAPT group) or aspirin alone (aspirin group) (75 -160 mg/day). Figure 1 summarizes the study flow. Thirteen patients (six assigned to the extended-DAPT group and seven to the aspirin group) could not been analysed (2 patients withdrew consent, and no information was available for 11 patients). Both baseline and procedural characteristics were well balanced between the two groups with the exception of age .75 years and LAD as the target vessel for revascularization, which were both significantly higher in the aspirin group ( Table 1) . The mean + age of the overall population was 64.1 + 11.1 years; 31.4% of the patients had diabetes mellitus, 17.4% had a clinical history of myocardial infarction, and 26.4% had a previous PCI. Overall, 5014 patients (36.24%) presented with an acute coronary syndrome, whereas PCI was elective in the remaining 63.86% of patients. Regarding baseline lesion and angiographic characteristics, 54.7% of the patients had multivessel disease. The left anterior descending coronary artery was the target vessel for revascularization in 60.2% of the patients. On average, each patient received 1.5 + 0.8 DES and mean total stent length was 18.72 + 7.45 mm per patient. The mean + SD diameter of the stent was 3.01 + 1.35 mm. First-generation DES (sirolimus-eluting and paclitaxel-eluting stents) were used in 34.3% of patients, and secondgeneration DES (zotarolimus-eluting, everolimus-eluting, or biodegradable polymer biolimus-eluting stents) in 65.7%. After the index procedure, the use of evidence-based medications was high: 93.9% of the patients were on a statin, 79.8% were on a b-blocker, and 74.7% were on an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Proton-pump inhibitors were used in half of the patients (48.3%). All patients completed a minimum of 6 months followup. Maximal follow-up (36 months post-randomization) was achieved in 43.7% of the patients.
The OPTIDUAL randomized trial
Outcomes during follow-up
Median follow-up for the total population was 1017 days (quartile 1 to quartile 3: 567.0-1096.0). Estimates for the composite and individual endpoints are reported in Table 2 . The primary composite outcome occurred in 40 patients in the extended-DAPT group vs. 52 in the aspirin group [5.8 vs. 7.5%; hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.50-1.28, P ¼ 0.17] (Figure 2 ). All-cause mortality did not differ between the two groups (2.3% for extended DAPT vs. 3.5% for aspirin; HR 0.65, 95% CI 0.34 -1.22, P ¼ 0.18) ( Figure 3A ). There were numerically lower rates of stroke ( Figure 3B ) and myocardial infarction ( Figure 3C ) with extended DAPT, which did not achieve statistical significance.
Major ISTH bleeding occurred in 14 patients in both the extended-DAPT group and the aspirin group (HR 0.98, 95% CI 0.47-2.05, P ¼ 0.95) ( Figure 3D ). Bleeding events categorized according to the various classifications (TIMI, GUSTO, and BARC) are described in Table 3 . Regardless of the classification used, there was no difference in bleeding rates between groups.
Results were similar and consistent when analyses taking into account informative censoring were made: HR 0.77, 95% CI 0.51 -1.16, P ¼ 0.22 for the primary composite outcome; HR 0.70, 95% CI 0.37 -1.34, P ¼ 0.28 for all-cause mortality; HR 0.80, 95% CI 0.24 -2.61, P ¼ 0.71 for stroke; HR 0.67, 95% CI 0.31 -1.43, P ¼ 0.30 for myocardial infarction; and HR 1.01, 95% CI 0.48 -2.11, P ¼ 0.98 for major ISTH bleeding.
The composite rate of death, myocardial infarction, or stroke (post hoc analysis) was 4.2% in the extended-DAPT group and 6.4% in the aspirin group (HR 0.64, 95% CI 0.40 -1.02, P ¼ 0.06) 
Continued
The OPTIDUAL randomized trial (Supplementary material online, Figure 1 ). Definite or probable stent thrombosis occurred in three patients in the extended-DAPT group (0.4%) and in one patient in the aspirin group (0.1%). Target vessel revascularization occurred in 5.0% in the extended-DAPT group and in 5.1% in the aspirin group (HR 0.97, 95% CI 0.61 -1.55).
The number of patients who had stopped clopidogrel at least at one visit was 183 (26.3%) (Figure 1) , and those who prematurely stopped clopidogrel during follow-up was 145 (20.9%) in the extended-DAPT group. Conversely, the number of patients who received clopidogrel or any other P2Y 12 blocker during follow-up in the aspirin group was 177 (25.7%, Figure 1) ; among those 92 (13.3%) were treated by clopidogrel at their last follow-up visit. Per-protocol and 'as treated' sensitivity analyses yielded results consistent with the ITT analysis (Supplementary material online, Figure 2 ).
Discussion
This randomized, multicentre trial compared outcomes between patients in whom clopidogrel was stopped at 12 months or continued after DES implantation on a background of aspirin therapy. There was no reduction in net adverse clinical events in the group in whom clopidogrel was continued compared with that in whom it was stopped 12 months after DES placement. There was a nominally lower rate of ischaemic outcomes (combination of death, myocardial infarction, or stroke, which was not a pre-specified outcome), . ............ ............ ............ ............ ........... ............ ............ ............ ........... ............ ............ ............ ........... ............ . Data regarding vessels treated were available for 616 patients in the group that was randomly assigned to extended DAPT and for 608 patients in the aspirin group. The OPTIDUAL randomized trial which did not achieve statistical superiority, and appears related to consistently lower rates of all ischaemic components, with point estimates for the HR of 0.65 for all-cause mortality, 0.67 for myocardial infarction, and 0.69 for stroke. Importantly, there was no apparent difference in the rates of major bleeding, which were identical in both groups. However, given the power of the trial, we cannot rule out up to a 50% reduction or a 28% increase in the primary outcome with extended DAPT. Stent thromboses were rare and the rate did not differ between the two groups. In the DAPT trial, 13 extended DAPT clearly reduced stent thrombosis rates, but the low rate of events in OPTIDUAL precludes conclusions. In terms of clinical efficacy, the OPTIDUAL results are consistent with the recent findings from the DAPT trial regarding the value of prolonging DAPT after DES placement, as the CI for the effects of extended DAPT on ischaemic outcomes includes the point estimate of 0.71 observed in the DAPT trial. With respect to all-cause mortality or bleeding, the confidence intervals of the effects observed in both trials largely overlap. The optimal duration of DAPT is an important clinical issue, given the large number of patients treated with DES, the costs and risks of antiplatelet therapy, the potentially life-threatening consequences of stent thrombosis, and the potential benefits of antiplatelet therapy in preventing ischaemic outcomes beyond stent thrombosis The rationale for a prolonged duration of DAPT is the prevention of stent thrombosis, but also the prevention of ischaemic events unrelated to the index coronary lesion. 13, 24 However, extending the duration of DAPT may also increase the risk of major bleeding. 7, 13 Recent randomized trials have explored shorter and longer durations of DAPT than 12 months. Shorter durations have been associated with lower bleeding rates but no clear difference in the rate of major adverse cardiac events. 25, 26 Conversely, treatment duration for
.12 months appears to reduce rates of major adverse cardiac events and major adverse cardiac and cerebrovascular events, and rates of stent thrombosis, albeit at the expense of increased major bleeding, 13, 26, 27 a result driven largely by the large DAPT trial. 13 In the DAPT trial, this finding was associated with a signal of increased mortality, 28 for which the mechanism remains debated. 29 Interestingly, in the OPTIDUAL trial, the rates of major bleeding were low and were very similar in both groups, regardless of the bleeding classification used. In addition, mortality was not increased with extended duration DAPT. In fact, the point estimate for the HR of all-cause mortality was 0.65 (95% CI 0.34-1.22). Since randomization was performed 12 months after PCI and only in patients who were event-free and on continued DAPT, OPTIDUAL may have selected a population at low risk of bleeding, particularly as DAPT is associated with a greater risk of bleeding in the first year after initiating therapy. 30, 31 However, given the relatively low event rate and wide CI, we cannot rule out an increase in bleeding risk of the same magnitude as that reported in the DAPT trial. 13 
Limitations
Several limitations must be considered when interpreting our results. First, termination of the trial before enrolment and follow-up were completed reduced the trial power. Our study was only powered to detect major differences in ischaemic and bleeding events and we absolutely cannot rule out clinically meaningful reductions in net adverse clinical outcomes, major adverse clinical outcomes, stent thrombosis, or mortality. In fact, there is a borderline but nonstatistically significant reduction in ischaemic outcomes with extended DAPT. However, this pertained to an outcome which was not pre-specified and therefore this finding from a post hoc analysis can only be viewed as hypothesis generating. Secondly, the use of third-generation DES was not mandated by protocol and there is evidence that the type of stent may have a bearing on the value of extending DAPT duration. However, the latest generation DES, relying on zotarolimus and everolimus-eluting stents, were used in the majority of the OPTIDUAL population and the outcomes observed in OPTIDUAL appear consistent across the various types of stents used. Third, the antiplatelet agents tested in OPTIDUAL were aspirin and clopidogrel. Recently, the PEGASUS trial 32 has found that in patients with a remote history of myocardial infarction, DAPT using ticagrelor was associated with benefit compared with single-antiplatelet therapy with aspirin. Whether ticagrelor would have provided greater efficacy, greater bleeding, or both compared with what clopidogrel achieved in OPTIDUAL remains speculative. 16 Fourth, the study was open-label, which is a less robust design than a double-blind trial, which requires substantially more resources for implementation. However, all clinical outcomes were adjudicated by an independent clinical event committee blinded to treatment assignment, and the components of the primary composite outcome all are objectively defined outcomes. Finally, a potentially important finding from the DAPT trial was the observation of an increased risk of stent thrombosis and major adverse cardiac outcomes in the weeks following discontinuation of clopidogrel, after both 12 and 30 months. 13 Unfortunately, we did not monitor event rates after treatment discontinuation, and therefore cannot comment on whether the excess risk of stent thrombosis related to treatment discontinuation is present or attenuated after extended DAPT. In the aspirin-only group, the Kaplan -Meier estimates do not suggest a clear increase in ischaemic events in the first few weeks following randomization and rather suggest a linear accrual of events, but the present study is underpowered for reliably assessing such a transient effect.
Conclusions
Extending DAPT duration for a median 22 months did not achieve statistical superiority compared with stopping clopidogrel at 12 months, with regards to net adverse clinical outcomes in patients free of a major cardiovascular or cerebrovascular event and major bleed 12 months after stent implantation.
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